E
Willow Biosciences Inc.
CANSF
$0.0062
$0.0032106.67%
E
Sell
11/18/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 11/18/2024 due to a decline in the valuation index, growth index and total return index. Operating cash flow declined 24.27% from -$535.7 to -$665.7.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 11/18/2024 due to a decline in the valuation index, growth index and total return index. Operating cash flow declined 24.27% from -$535.7 to -$665.7.
D
Sell
10/24/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 10/24/2024 due to an increase in the total return index and volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 10/24/2024 due to an increase in the total return index and volatility index.
E
Sell
10/9/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 10/9/2024 due to a decline in the volatility index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 10/9/2024 due to a decline in the volatility index.
D
Sell
9/19/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 9/19/2024 due to an increase in the volatility index and total return index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 9/19/2024 due to an increase in the volatility index and total return index.
E
Sell
9/4/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 9/4/2024 due to a decline in the volatility index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 9/4/2024 due to a decline in the volatility index.
D
Sell
8/16/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 8/16/2024 due to a significant increase in the growth index, valuation index and total return index. Total revenue increased 1,883.6% from $37.8 to $749.8, operating cash flow increased 58.71% from -$1.3M to -$535.7, and EBIT increased 41.99% from -$1.82M to -$1.06M.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 8/16/2024 due to a significant increase in the growth index, valuation index and total return index. Total revenue increased 1,883.6% from $37.8 to $749.8, operating cash flow increased 58.71% from -$1.3M to -$535.7, and EBIT increased 41.99% from -$1.82M to -$1.06M.
E
Sell
6/4/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 6/4/2024 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.37 to 0.88, and the quick ratio declined from 2.18 to 1.29.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 6/4/2024 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.37 to 0.88, and the quick ratio declined from 2.18 to 1.29.
D
Sell
5/29/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 5/29/2024 due to an increase in the valuation index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 5/29/2024 due to an increase in the valuation index.
E
Sell
5/14/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 5/14/2024 due to a decline in the valuation index and growth index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 5/14/2024 due to a decline in the valuation index and growth index.
D
Sell
4/29/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 4/29/2024 due to an increase in the valuation index, volatility index and total return index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 4/29/2024 due to an increase in the valuation index, volatility index and total return index.
E
Sell
4/11/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 4/11/2024 due to a major decline in the growth index, valuation index and volatility index. Total revenue declined 86.99% from $502.5 to $65.4, EBIT declined 21.27% from -$1.67M to -$2.02M, and earnings per share declined from -$0.0134 to -$0.0143.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 4/11/2024 due to a major decline in the growth index, valuation index and volatility index. Total revenue declined 86.99% from $502.5 to $65.4, EBIT declined 21.27% from -$1.67M to -$2.02M, and earnings per share declined from -$0.0134 to -$0.0143.
D
Sell
2/22/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 2/22/2024 due to an increase in the total return index and volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 2/22/2024 due to an increase in the total return index and volatility index.
E
Sell
1/31/2024Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 1/31/2024 due to a decline in the volatility index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 1/31/2024 due to a decline in the volatility index.
D
Sell
1/16/2024Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 1/16/2024 due to a substantial increase in the growth index, total return index and volatility index. Total revenue increased 400% from $100.5 to $502.5, EBIT increased 38.53% from -$2.72M to -$1.67M, and earnings per share increased from -$0.0216 to -$0.0134.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 1/16/2024 due to a substantial increase in the growth index, total return index and volatility index. Total revenue increased 400% from $100.5 to $502.5, EBIT increased 38.53% from -$2.72M to -$1.67M, and earnings per share increased from -$0.0216 to -$0.0134.
E
Sell
9/28/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 9/28/2023 due to a decline in the total return index, volatility index and valuation index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 9/28/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell
9/13/2023Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 9/13/2023 due to an increase in the total return index and volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 9/13/2023 due to an increase in the total return index and volatility index.
E
Sell
8/29/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 8/29/2023 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.04 to 0.1, and the quick ratio declined from 6.57 to 3.83.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 8/29/2023 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.04 to 0.1, and the quick ratio declined from 6.57 to 3.83.
D
Sell
7/26/2023Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 7/26/2023 due to an increase in the volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 7/26/2023 due to an increase in the volatility index.
E
Sell
7/11/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 7/11/2023 due to a decline in the volatility index and total return index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 7/11/2023 due to a decline in the volatility index and total return index.
D
Sell
6/22/2023Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 6/22/2023 due to an increase in the total return index and volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 6/22/2023 due to an increase in the total return index and volatility index.
E
Sell
6/7/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index.
D
Sell
5/23/2023Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 5/23/2023 due to an increase in the volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 5/23/2023 due to an increase in the volatility index.
E
Sell
5/18/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 5/18/2023 due to a decline in the volatility index and growth index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 5/18/2023 due to a decline in the volatility index and growth index.
D
Sell
4/3/2023Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index and total return index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Willow Biosciences Inc. (CANSF) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D on 02/08/2023.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D on 02/08/2023.
D
Sell
11/10/2022Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 11/10/2022 due to a large increase in the growth index and valuation index. EBIT increased 10.12% from -$3.53M to -$3.17M, and operating cash flow increased 6.14% from -$2.67M to -$2.51M.
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 11/10/2022 due to a large increase in the growth index and valuation index. EBIT increased 10.12% from -$3.53M to -$3.17M, and operating cash flow increased 6.14% from -$2.67M to -$2.51M.
D
Sell
8/17/2022Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to D- from D on 8/17/2022 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.019 to -$0.0235, total capital declined 12.75% from $22.29M to $19.45M, and operating cash flow declined 10.64% from -$2.41M to -$2.67M.
Willow Biosciences Inc. (CANSF) was downgraded to D- from D on 8/17/2022 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.019 to -$0.0235, total capital declined 12.75% from $22.29M to $19.45M, and operating cash flow declined 10.64% from -$2.41M to -$2.67M.
D
Sell
7/13/2022Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to D from D+ on 7/13/2022 due to a decline in the total return index and volatility index.
Willow Biosciences Inc. (CANSF) was downgraded to D from D+ on 7/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/20/2022Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D+ from D on 5/20/2022 due to a significant increase in the efficiency index, valuation index and growth index. Net income increased 43.17% from -$4.12M to -$2.34M, earnings per share increased from -$0.0334 to -$0.019, and operating cash flow increased 40% from -$4.02M to -$2.41M.
Willow Biosciences Inc. (CANSF) was upgraded to D+ from D on 5/20/2022 due to a significant increase in the efficiency index, valuation index and growth index. Net income increased 43.17% from -$4.12M to -$2.34M, earnings per share increased from -$0.0334 to -$0.019, and operating cash flow increased 40% from -$4.02M to -$2.41M.
D
Sell
5/5/2022Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and volatility index.
D
Sell
4/20/2022Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0238 to -$0.0334, debt to equity increased from 0.01 to 0.02, and operating cash flow declined 20.15% from -$3.35M to -$4.02M.
Willow Biosciences Inc. (CANSF) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0238 to -$0.0334, debt to equity increased from 0.01 to 0.02, and operating cash flow declined 20.15% from -$3.35M to -$4.02M.
D
Sell
11/17/2021Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 11/17/2021 due to an increase in the growth index and solvency index. Debt to equity declined from 0.02 to 0.01, and operating cash flow increased 18.18% from -$4.09M to -$3.35M.
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 11/17/2021 due to an increase in the growth index and solvency index. Debt to equity declined from 0.02 to 0.01, and operating cash flow increased 18.18% from -$4.09M to -$3.35M.
D
Sell
11/8/2021Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and total return index. Operating cash flow declined 50.25% from -$2.72M to -$4.09M, and EBIT declined 25.65% from -$3.74M to -$4.7M.
Willow Biosciences Inc. (CANSF) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and total return index. Operating cash flow declined 50.25% from -$2.72M to -$4.09M, and EBIT declined 25.65% from -$3.74M to -$4.7M.
D
Sell
11/16/2020Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 11/16/2020 due to a substantial increase in the growth index. Earnings per share increased from -$0.0921 to -$0.0751.
Willow Biosciences Inc. (CANSF) was upgraded to D from D- on 11/16/2020 due to a substantial increase in the growth index. Earnings per share increased from -$0.0921 to -$0.0751.
D
Sell
10/27/2020Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 10/27/2020 due to an increase in the total return index, volatility index and valuation index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 10/27/2020 due to an increase in the total return index, volatility index and valuation index.
E
Sell
8/14/2020Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0134 to -$0.0939, and the quick ratio declined from 9.7 to 8.97.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0134 to -$0.0939, and the quick ratio declined from 9.7 to 8.97.
D
Sell
5/4/2020Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 5/4/2020 due to an increase in the growth index and volatility index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E+ on 5/4/2020 due to an increase in the growth index and volatility index.
E
Sell
3/26/2020Downgrade
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 3/26/2020 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 196.05% from -$1.12M to -$3.31M, earnings per share declined from -$0.0106 to -$0.0299, and net income declined 181.8% from -$832.6 to -$2.35M.
Willow Biosciences Inc. (CANSF) was downgraded to E+ from D- on 3/26/2020 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 196.05% from -$1.12M to -$3.31M, earnings per share declined from -$0.0106 to -$0.0299, and net income declined 181.8% from -$832.6 to -$2.35M.
D
Sell
1/2/2020Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to D- from E on 1/2/2020 due to an increase in the volatility index and total return index.
Willow Biosciences Inc. (CANSF) was upgraded to D- from E on 1/2/2020 due to an increase in the volatility index and total return index.
E
Sell
10/2/2019Upgraded
Willow Biosciences Inc. (CANSF) was upgraded to E from E- on 10/2/2019 due to a noticeable increase in the solvency index, valuation index and efficiency index. Total capital increased 3,073.89% from $618.1 to $19.62M, the quick ratio increased from 1.12 to 13.23, and debt to equity declined from 0.85 to 0.02.
Willow Biosciences Inc. (CANSF) was upgraded to E from E- on 10/2/2019 due to a noticeable increase in the solvency index, valuation index and efficiency index. Total capital increased 3,073.89% from $618.1 to $19.62M, the quick ratio increased from 1.12 to 13.23, and debt to equity declined from 0.85 to 0.02.
E
Sell
7/12/2019None
Willow Biosciences Inc. (CANSF) was downgraded to E- from U on 07/12/2019.
Willow Biosciences Inc. (CANSF) was downgraded to E- from U on 07/12/2019.
OTC PK
04/10/2025 1:41PM Eastern
Quotes delayed
